Skip to content
LATEST
Health

Amplia Therapeutics Secures Ethics Approval for Pancreatic Cancer Drug Trial

Amplia Therapeutics has received approval to begin a new clinical trial for its pancreatic cancer drug, narmafotinib, aiming to secure data for future U.S.

Amplia Therapeutics Secures Ethics Approval for Pancreatic Cancer Drug Trial

Amplia Therapeutics has received ethics approval to initiate the "ACCENT-Mini" clinical trial, which will evaluate the efficacy and safety of its lead drug candidate, narmafotinib, in combination with chemotherapy for patients with metastatic pancreatic cancer. The trial will commence patient recruitment across three Australian clinical sites to establish an optimal daily-dosing regimen.

This study follows previous clinical data indicating that narmafotinib, a Focal Adhesion Kinase (FAK) inhibitor, achieved a 36% tumor response rate and a median overall survival of 11.1 months when administered with standard chemotherapy. By inhibiting FAK, the drug aims to reduce the fibrotic tissue surrounding solid tumors, potentially increasing the efficacy of existing chemotherapy treatments.

Food and Drug Administration

The company expects to generate safety and pharmacokinetic data from this trial by late Q1 or early Q2 of 2027. These results are intended to support a formal protocol submission to the U.S. Food and Drug Administration (FDA) for a larger, registrational study.

Strategic interest in this trial is heightened by Strategic interest in this trial is heightened by the prevalence of KRAS gene mutations in over 90% of pancreatic cancer cases. As the FDA continues to approve new KRAS-targeting therapies, the potential for narmafotinib to function as a complementary treatment in combination regimens remains a key focus for the company’s clinical development pipeline.

Successful outcomes from the ACCENT-Mini trial are critical for the company’s regulatory strategy. The data will serve as the primary evidence required to design a pivotal study, which is a necessary precursor to seeking commercial approval for the drug in the United States market.

More stories

Latest news